The Emerging Role of HE4 in the Evaluation of Epithelial Ovarian and Endometrial Carcinomas

Overview

Journal Oncology (Williston Park)

Specialty Oncology

Date 2013 Aug 6

PMID 23909069

Citations 33

Authors

Archana R Simmons

Keith Baggerly

Robert C Bast Jr

Affiliations

Soon will be listed here.

Abstract

HE4 (human epididymis protein 4) is overexpressed in both ovarian and endometrial cancers. Levels of the shed HE4 protein are elevated in sera from ovarian and endometrial cancer patients. HE4 is less frequently elevated than cancer antigen 125 (CA 125) in benign gynecologic conditions and is found in a fraction of endometrial and ovarian cancers that lack CA 125 expression. Consequently, HE4 has emerged as an important biomarker that complements CA 125 in discriminating between benign and malignant pelvic masses, monitoring response to treatment, and detecting recurrences of both ovarian and endometrial cancer. The "risk of ovarian malignancy algorithm" (ROMA) incorporates CA 125, HE4, and menopausal status to distinguish benign from malignant adnexal masses, and has been approved by the US Food and Drug Administration to aid in referring patients who are likely to have ovarian cancer to specially trained gynecologic oncologists for surgery. HE4 also promises to augment the sensitivity of CA 125 for detecting early-stage ovarian cancer. In this review, we discuss the discovery and biologic significance of HE4 and evaluate available evidence regarding the utility of HE4 as a biomarker for ovarian and endometrial cancer.

Citing Articles

The NF-κB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancer.

Kim K, Khazan N, McDowell J, Snyder C, Miller J, Singh R PLoS One. 2024; 19(12):e0314564.

PMID: 39621651 PMC: 11611113. DOI: 10.1371/journal.pone.0314564.

Diagnostic performance of a modified O-RADS classification system for adnexal lesions incorporating clinical features.

Wu M, Cai S, Zhu L, Yang D, Huang S, Huang X Abdom Radiol (NY). 2024; 50(2):953-965.

PMID: 39164457 DOI: 10.1007/s00261-024-04538-8.

Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer.

Han C, Bedia J, Yang W, Hawley S, Bergan L, Hopper M Br J Cancer. 2024; 130(5):861-868.

PMID: 38195887 PMC: 10912308. DOI: 10.1038/s41416-023-02560-z.

Roles of Antimicrobial Peptides in Gynecological Cancers.

Zhao C, Yan S, Song Y, Xia X Int J Mol Sci. 2022; 23(17).

PMID: 36077500 PMC: 9456504. DOI: 10.3390/ijms231710104.

Machine learning algorithms enhance the specificity of cancer biomarker detection using SERS-based immunoassays in microfluidic chips.

Banaei N, Moshfegh J, Mohseni-Kabir A, Houghton J, Sun Y, Kim B RSC Adv. 2022; 9(4):1859-1868.

PMID: 35516124 PMC: 9059745. DOI: 10.1039/c8ra08930b.

References

Lowe K, Shah C, Wallace E, Anderson G, Paley P, McIntosh M . Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17(9):2480-7. PMC: 2632599. DOI: 10.1158/1055-9965.EPI-08-0150. View

Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P . Does HE4 have a role as biomarker in the recurrence of ovarian cancer?. Tumour Biol. 2012; 33(6):2117-23. DOI: 10.1007/s13277-012-0471-7. View

Zanotti L, Bignotti E, Calza S, Bandiera E, Ruggeri G, Galli C . Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin Chem Lab Med. 2012; 50(12):2189-98. DOI: 10.1515/cclm-2011-0757. View

Chudecka-Glaz A, Rzepka-Gorska I, Wojciechowska I . Human epididymal protein 4 (HE4) is a novel biomarker and a promising prognostic factor in ovarian cancer patients. Eur J Gynaecol Oncol. 2012; 33(4):382-90. View

Moore R, Miller M, Eklund E, Lu K, Bast Jr R, Lambert-Messerlian G . Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol. 2012; 206(4):349.e1-7. PMC: 3987114. DOI: 10.1016/j.ajog.2011.12.028. View

Anderson G, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe J . Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst. 2010; 102(1):26-38. PMC: 2802285. DOI: 10.1093/jnci/djp438. View

Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A . Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10(4):327-40. DOI: 10.1016/S1470-2045(09)70026-9. View

Trudel D, Tetu B, Gregoire J, Plante M, Renaud M, Bachvarov D . Human epididymis protein 4 (HE4) and ovarian cancer prognosis. Gynecol Oncol. 2012; 127(3):511-5. DOI: 10.1016/j.ygyno.2012.09.003. View

Lin J, Qin J, Sangvatanakul V . Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2012; 167(1):81-5. DOI: 10.1016/j.ejogrb.2012.10.036. View

10.

Moore R, Miller M, Steinhoff M, Skates S, Lu K, Lambert-Messerlian G . Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol. 2012; 206(4):351.e1-8. PMC: 3985608. DOI: 10.1016/j.ajog.2011.12.029. View

11.

Cramer D, Bast Jr R, Berg C, Diamandis E, Godwin A, Hartge P . Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila). 2011; 4(3):365-74. PMC: 3085251. DOI: 10.1158/1940-6207.CAPR-10-0195. View

12.

Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M . The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?. Clin Chem Lab Med. 2011; 49(3):521-5. DOI: 10.1515/CCLM.2011.075. View

13.

Van Gorp T, Veldman J, Van Calster B, Cadron I, Leunen K, Amant F . Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. Eur J Cancer. 2012; 48(11):1649-56. DOI: 10.1016/j.ejca.2011.12.003. View

14.

Creutzberg C, van Putten W, Koper P, Lybeert M, Jobsen J, Warlam-Rodenhuis C . Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003; 89(2):201-9. DOI: 10.1016/s0090-8258(03)00126-4. View

15.

Hellstrom I, Heagerty P, Swisher E, Liu P, Jaffar J, Agnew K . Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms. Cancer Lett. 2010; 296(1):43-8. PMC: 3156592. DOI: 10.1016/j.canlet.2010.03.013. View

16.

Drapkin R, von Horsten H, Lin Y, C Mok S, Crum C, Welch W . Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65(6):2162-9. DOI: 10.1158/0008-5472.CAN-04-3924. View

17.

Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F . Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010; 28(13):2159-66. PMC: 2860434. DOI: 10.1200/JCO.2008.19.2484. View

18.

Lu R, Sun X, Xiao R, Zhou L, Gao X, Guo L . Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun. 2012; 419(2):274-80. DOI: 10.1016/j.bbrc.2012.02.008. View

19.

Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R . The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol. 2012; 34(1):571-6. DOI: 10.1007/s13277-012-0583-0. View

20.

Andersen M, Goff B, Lowe K, Scholler N, Bergan L, Drescher C . Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2009; 116(3):378-83. PMC: 2822097. DOI: 10.1016/j.ygyno.2009.10.087. View